Fischer Medical Q4 FY26 Results (NSE: FISCHER)
Signal: Slipped to loss
The read
Consolidated Q4FY26 shows huge revenue of ₹9,773 Cr but a deep net loss of ₹710 Cr driven by massive 'Other Expenses' and finance costs — the business appears in a high-cost expansion phase; standalone operations are deeply loss-making with negative EBITDA, while the consolidated entity benefits from subsidiary contributions but still loses money at net level.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹97.73 Cr | 98.76% | -3.33% |
| EBIT | ₹-2.25 Cr | ||
| Net profit | ₹-7.1 Cr | -641.98% | |
| EPS | ₹-0.11 |
P&L walk
Consolidated Q4 revenue ₹9,773 Cr down slightly QoQ; operating loss of ₹225 Cr vs prior year profit; net loss of ₹710 Cr due to huge 'Other Expenses' of ₹2,168 Cr and finance costs ₹361 Cr.
Key positives
- Consolidated full-year revenue grew ~178% to ₹30,858 Cr from ₹11,070 Cr.
Key concerns
- Consolidated net loss of ₹710 Cr in Q4 vs profit of ₹131 Cr in Q4 last year.
- Standalone operations deeply loss-making: EBITDA margin -181% in Q4.
- Finance costs exploded +1,494% YoY in consolidated Q4.
- Huge 'Other Expenses' of ₹2,168 Cr in consolidated Q4, unclear what drives them.
- Negative operating cash flow of -₹572 lakh in FY26 standalone.
Research and educational content only. Not investment advice.